Individualizing therapy for neovascular age-related macular degeneration with aflibercept

Trial Profile

Individualizing therapy for neovascular age-related macular degeneration with aflibercept

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms VITAL
  • Most Recent Events

    • 11 Jul 2016 Last checked against ClinicalTrials.gov record.
    • 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Feb 2016 Accrual to date is 96% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top